APOC3 APOC3 C-482T

APOC3 C-482T — When Your Body Can't Turn Off the Fat Signal

Apolipoprotein C-III (apoCIII) is the body's master brake on triglyceride
clearance. It coats triglyceride-rich VLDL particles and inhibits the
lipoprotein lipase | The enzyme that breaks down triglycerides in blood,
releasing fatty acids for tissues
that would otherwise clear them. After a meal, healthy physiology suppresses
apoCIII secretion — letting triglycerides clear quickly. The rs2854117
variant disrupts that suppression, keeping apoCIII elevated and triglycerides
circulating longer.

The Mechanism

The APOC3 gene sits on chromosome 11 in a cluster with APOA1, APOA4, and
APOA5. Its promoter contains a
negative insulin response element (nIRE) | A DNA sequence where insulin
binding normally represses gene transcription
that ordinarily drives down APOC3 output after eating. The C-482T variant
(T allele at rs2854117) lies within this nIRE, altering its sequence and
blunting the insulin signal that should silence APOC3. The result is
persistently elevated apoCIII protein, which keeps VLDL particles
circulating and slows triglyceride clearance from the bloodstream.

The -482 position is in strong linkage disequilibrium with rs2854116
(T-455C), and the two variants are usually studied together as part of an
APOC3 promoter haplotype. Both sit within the same nIRE, and their combined
effect on insulin-mediated suppression appears additive.

The Evidence

A 2003 prospective cohort study in 502 adults | Waterworth et al. Variants
in the APOC3 promoter insulin responsive element modulate insulin secretion
and lipids. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003 found that T allele homozygotes
had a 33% lower 30-minute insulin increment after glucose challenge, and
approximately 10% higher non-esterified fatty acid (NEFA) levels, compared
to CC homozygotes. Both variants (at -482 and -455) also interacted with
smoking to worsen fasting triglycerides.

A 2001 epidemiological study in 983 French adults | Dallongeville et al.
Polymorphisms in the insulin response element of APOC-III gene promoter
influence the correlation between insulin and triglycerides. Arteriosclerosis,
Thrombosis, and Vascular Biology, 2001
confirmed that the -482 T allele modifies the relationship between plasma
insulin and triglyceride-rich LpCIII:B particles, particularly in women.

The most direct disease-risk evidence comes from a 2025 Chinese case-control
study in 440 participants | Ye et al. Associations between APOC3 and ANGPTL8
gene polymorphisms with MASLD risk. 2025,
which found that CT+TT carriers had 1.9-fold higher odds of metabolic
dysfunction-associated steatotic liver disease (MASLD) compared with CC
carriers (OR 1.9, 95% CI 1.2–3.2), with triglycerides mediating 62.6% of
that genetic effect.

Pharmacogenomic data from the GOLDN trial | Liu et al.
Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid
responses to fenofibrate. Pharmacogenetics and Genomics, 2009 showed that the T minor allele
is associated with a blunted triglyceride-lowering response to fenofibrate
(p=0.026), unlike other variants in the same cluster which enhance the
response. This suggests the -482 variant alters the transcriptional pathway
fenofibrate relies on.

Evidence is mixed on broader cardiovascular endpoints: a meta-analysis
found no significant association with ischemic stroke | Zhang et al.
The impact of APOA5, APOB, APOC3 and ABCA1 gene polymorphisms on ischemic
stroke. Gene, 2017, and studies
in European cohorts have not consistently shown a NAFLD/liver-fat
association, suggesting ethnic and dietary context modulate the phenotypic
expression.

Practical Actions

T allele carriers should focus on the two levers most directly linked to
apoCIII activity: dietary fat quality and post-meal triglyceride clearance.
Limiting refined carbohydrates and fructose is particularly relevant because
both raise apoCIII transcription independently of the promoter variant.
Long-chain omega-3 fatty acids (EPA and DHA) suppress apoCIII at the
transcriptional level, partially compensating for the blunted insulin signal.

Fasting triglyceride testing is the most direct way to track phenotypic
expression of this variant. Levels consistently above 150 mg/dL suggest the
variant is having a meaningful effect and warrant dietary intervention.
Fenofibrate may have a reduced effect in T carriers; if fibrate therapy is
being considered, this variant is worth noting to the prescribing clinician.

Interactions

rs2854117 is in strong linkage disequilibrium with rs2854116 (T-455C,
the other APOC3 promoter nIRE variant). Carriers of the T allele at
rs2854117 are very likely to also carry the C allele at rs2854116. Studies
generally show additive effects on apoCIII dysregulation when both promoter
variants are co-inherited. The APOC3 3'-SstI variant (rs5128) operates
through a different mechanism (post-transcriptional or 3'-regulatory) and
has independent effects on VLDL — its effect can stack with the promoter
haplotype.

The APOA5 rs662799 variant is a frequent companion in hypertriglyceridemia
genetic panels and encodes a different step in the VLDL-triglyceride axis.
When rs662799 risk allele co-occurs with the rs2854117 T allele, the
combined triglyceride burden is likely additive, though published compound
analyses are limited.